1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Byoung Chul Cho, K.H. Lee, E.K. Cho, Dongwook Kim, Jin Sun Lee, J-Y. Han, S-W. Kim, Alexander I. Spira, Eric B. Haura, Joshua K. Sabari, Rachel E. Sanborn, Joshua Bauml, Jorge Gómez, Patricia Lorenzini, Jeffrey R. Infante, John Xie, Nahor Haddish‐Berhane, Meena Thayu, Roland E. Knoblauch, K. Park
Topics & Concepts
MedicineRashInternal medicineCombination therapyGastroenterologyResponse Evaluation Criteria in Solid Tumorsnon-small cell lung cancer (NSCLC)Progressive diseaseAdverse effectInterim analysisOncologyRegimenT790MLung cancerCancerGefitinibEpidermal growth factor receptorClinical trialChemotherapyA549 cellLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes